RNAC
HEALTHCARECartesian Therapeutics Inc
$8.34+0.95 (+12.86%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving RNAC Today?
No stock-specific AI insight has been generated for RNAC yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$5.60$15.57
$8.34
Fundamentals
Market Cap$245M
P/E Ratio—
EPS$-5.80
Dividend Yield—
Dividend / Share—
ROE-70.3%
Profit Margin—
Debt / Equity—
Trading
Volume278K
Avg Volume (10D)—
Shares Outstanding29.4M
RNAC News
20 articles- Cartesian Therapeutics Announces New Employment Inducement GrantsYahoo Finance·May 4, 2026
- Cartesian Therapeutics, Inc. (RNAC) Reports Q1 Loss, Lags Revenue EstimatesYahoo Finance·Apr 30, 2026
- Cartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateYahoo Finance·Apr 30, 2026
- Cartesian Therapeutics, Inc. (RNAC) Soars 10.3%: Is Further Upside Left in the Stock?Yahoo Finance·Apr 20, 2026
- Generalized Myasthenia Gravis Market on the Brink of Change: 8 Promising Late-Stage Drugs Signal a New Treatment Era | DelveInsightGlobeNewswire Inc.·Apr 15, 2026
- Cartesian Therapeutics Reports Full Year 2025 Financial Results and Provides Business UpdateYahoo Finance·Mar 9, 2026
- Cartesian Therapeutics to Participate in Upcoming Investor ConferencesYahoo Finance·Feb 23, 2026
- Generalized Myasthenia Gravis Market Outlook Shows Strong Momentum During the Forecast Period (2025–2034) Driven by Novel Immunotherapies | DelveInsightYahoo Finance·Jan 14, 2026
- Cartesian Therapeutics, Inc. (RNAC) Upgraded to Buy: What Does It Mean for the Stock?Yahoo Finance·Jan 14, 2026
- Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 OutlookYahoo Finance·Jan 9, 2026
- Cartesian Therapeutics Announces the Appointment of Adrian Bot to Board of DirectorsYahoo Finance·Dec 18, 2025
- Here's Why We're Watching Cartesian Therapeutics' (NASDAQ:RNAC) Cash Burn SituationYahoo Finance·Dec 5, 2025
- Cartesian Therapeutics Announces Strong Efficacy Signal in Phase 2 Trial of Descartes-08 in Patients with SLE and Expansion of Clinical Development into MyositisYahoo Finance·Nov 13, 2025
- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) insiders have significant skin in the game with 58% ownershipYahoo Finance·Nov 8, 2025
- Cartesian Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business UpdateYahoo Finance·Nov 6, 2025
- Cartesian Therapeutics Announces Carsten Brunn, Ph.D., Named as Chairman of the Company’s Board of DirectorsYahoo Finance·Oct 30, 2025
- CAR T-cell Therapy Market Forecasts Indicate Strong Growth Trajectory in the 7MM During the Forecast Period (2025-2034) | DelveInsightYahoo Finance·Oct 28, 2025
- Repligen (RGEN) Q3 Earnings and Revenues Surpass EstimatesYahoo Finance·Oct 28, 2025
- Strength Seen in Cartesian Therapeutics, Inc. (RNAC): Can Its 8.2% Jump Turn into More Strength?Yahoo Finance·Oct 21, 2025
- Cartesian Therapeutics Announces New Employment Inducement GrantYahoo Finance·Oct 3, 2025
All 20 articles loaded
Price Data
Open$7.46
Previous Close$7.39
Day High$8.42
Day Low$7.38
52 Week High$15.57
52 Week Low$5.60
52-Week Range
$5.60$15.57
$8.34
Fundamentals
Market Cap$245M
P/E Ratio—
EPS$-5.80
Dividend Yield—
Dividend / Share—
ROE-70.3%
Profit Margin—
Debt / Equity—
Trading
Volume278K
Avg Volume (10D)—
Shares Outstanding29.4M
About Cartesian Therapeutics Inc
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company is headquartered in Watertown, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—